The US Food and Drug Administration (FDA) has approved Neobiosis’ investigational new drug (IND) application for ViXome to treat post-Covid-19 syndrome (also known as long Covid).

ViXome is an acellular product derived from amniotic fluid.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It comprises a heterogeneous population of growth factors, exosomes, cytokines, microRNAs and chemokines.

In pre-clinical testing, the therapy showed potent immunomodulatory and pro-reparative effects.

Neobiosis chief scientific officer and CEO Dr Ian White stated: “This is an important milestone for Neobiosis and we are excited to be advancing ViXome, a refined product extracted from thoroughly screened and sterile amniotic fluid obtained at the time of C-section [Caesarean delivery] of full-term pregnancies, into clinical development.

“We are eager to confirm our preclinical data in the clinic and expect to begin enrolling patients in Phase I during the second quarter of 2024.”

The company stated that the Phase I/IIa trial will thoroughly evaluate the therapy’s clinical efficacy and safety.

It developed perinatal tissue-derived therapeutics to transform a broad spectrum of diseases treatment of high unmet medical needs.

The company’s products are processed in advanced FDA-inspected, FDA-registered, cGMP (current good manufacturing process)-compliant cleanrooms in Gainesville, Florida, US.

Its research and development activities are performed at the University of Florida’s Sid Martin Innovate Biotechnology Institute in Alachua.

Dr White added: “We are excited to be one of the first companies in the US to advance a potential therapeutic for the treatment of a devastating disease that already affects over 300 million people worldwide.”